Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience.

Multiple sclerosis and related disorders·2026
Same author

Long-Term Outcomes of Deep Brain Stimulation in Woodhouse-Sakati Syndrome.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal of neurology·2026
Same author

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.

CNS drugs·2026
Same author

PhysioMio: bilateral and longitudinal HD-sEMG dataset of 16 hand gestures from 48 stroke patients.

Scientific data·2026

Related Experiment Video

Updated: May 13, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Multiple sclerosis in the Arabian Gulf countries: a consensus statement.

Saeed Bohlega1, Jihad Inshasi, Abdel Rahman Al Tahan

  • 1King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia, boholega@kfshrc.edu.sa.

Journal of Neurology
|March 19, 2013
PubMed
Summary

Multiple Sclerosis (MS) prevalence is rising in the Arabian Gulf, shifting from a previously low-risk zone. Neurologists convened to discuss epidemiology and establish regional management guidelines for this evolving neurological condition.

Area of Science:

  • Neurology
  • Epidemiology

Background:

  • The Arabian Gulf Region was historically considered low-risk for Multiple Sclerosis (MS) based on the Kurtzke classification.

More Related Videos

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: May 13, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

  • Recent data indicate a shift, with moderate-to-high MS prevalence (31-55 per 10,0000) and increasing incidence in the region.
  • The relapsing-remitting MS course is more common than the primary progressive type, with a ratio of 2.5:1.